These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31711836)

  • 1. External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system.
    Leo MC; McMullen CK; O'Keeffe-Rosetti M; Weinmann S; Garg T; Nielsen ME
    Urol Oncol; 2020 Feb; 38(2):39.e21-39.e27. PubMed ID: 31711836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.
    Ravvaz K; Walz ME; Weissert JA; Downs TM
    J Urol; 2017 Oct; 198(4):824-831. PubMed ID: 28433642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
    Zhang G; Steinbach D; Grimm MO; Horstmann M
    World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
    Soukup V; Čapoun O; Cohen D; Hernández V; Burger M; Compérat E; Gontero P; Lam T; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R; Babjuk M
    Eur Urol Focus; 2020 May; 6(3):479-489. PubMed ID: 30470647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
    Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Ojea A; Portillo J; Montesinos M; Gonzalez M; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
    Eur Urol; 2011 Sep; 60(3):423-30. PubMed ID: 21621906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.
    Jobczyk M; Stawiski K; Fendler W; Różański W
    Cancer Med; 2020 Jun; 9(11):4014-4025. PubMed ID: 32216043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.
    Xylinas E; Kent M; Kluth L; Pycha A; Comploj E; Svatek RS; Lotan Y; Trinh QD; Karakiewicz PI; Holmang S; Scherr DS; Zerbib M; Vickers AJ; Shariat SF
    Br J Cancer; 2013 Sep; 109(6):1460-6. PubMed ID: 23982601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.
    Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
    World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.
    Ieda T; Muto S; Shimizu F; Taguri M; Yanada S; Kitamura K; Terai K; Saito K; Ogishima T; Nagata M; Ide H; Okegawa T; Wakumoto Y; Sakamoto Y; Tsujimura A; Yamaguchi R; Nutahara K; Horie S
    EBioMedicine; 2016 Oct; 12():98-104. PubMed ID: 27614395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EORTC Risk Model to Predict Progression in Patients With Non-Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?
    Busato Júnior WF; Almeida GL; Ribas CA; Ribas Filho JM; De Cobelli O
    Clin Genitourin Cancer; 2016 Apr; 14(2):176-82. PubMed ID: 26444918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of the EORTC and CUETO Models to Predict Recurrence and Progression in High-risk Non-muscle-invasive Bladder Cancer Patients.
    Pazır Y; Esmeray A; Gelmis M; Caglar U; Ozgor F; Sarılar O; Akbulut F
    Urol J; 2024 May; 21(3):169-174. PubMed ID: 38493314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-muscle invasive bladder cancer risk stratification.
    Isharwal S; Konety B
    Indian J Urol; 2015; 31(4):289-96. PubMed ID: 26604439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
    Soukup V; Čapoun O; Cohen D; Hernández V; Babjuk M; Burger M; Compérat E; Gontero P; Lam T; MacLennan S; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R
    Eur Urol; 2017 Nov; 72(5):801-813. PubMed ID: 28457661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
    Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
    BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk estimation of multiple recurrence and progression of non muscle invasive bladder carcinoma using new mathematical models.
    Luján S; Santamaría C; Pontones JL; Ruiz-Cerdá JL; Trassierra M; Vera-Donoso CD; Solsona E; Jiménez-Cruz F
    Actas Urol Esp; 2014 Dec; 38(10):647-54. PubMed ID: 24930059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A larger detrusor wall thickness increases the risk of non muscle invasive bladder cancer recurrence and progression: result from a multicenter observational study.
    Cicione A; Manno S; Ucciero G; Cantiello F; Damiano R; Lima E; Posti A; Balloni F; De Nunzio C
    Minerva Urol Nefrol; 2018 Jun; 70(3):310-318. PubMed ID: 29241311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1.
    Almeida GL; Busato WF; Ribas CM; Ribas JM; De Cobelli O
    Int Braz J Urol; 2016; 42(5):932-941. PubMed ID: 27509372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.